Study Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
Interested in this trial?
Submit an InquiryInterventions
CD7CAR T cellsBIOLOGICAL
CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Lu Daopei Hospital | Langfang | Hebei | China |